Changes of urinary phospholipids in the chronic kidney disease patients
- 11 September 2013
- journal article
- research article
- Published by Taylor & Francis in Biomarkers
- Vol. 18 (7) , 601-606
Abstract
Objective: To evaluate whether urinary phospholipids could be regarded as biomarkers of chronic kidney disease. Materials and methods: Thirteen healthy volunteers and 26 consecutive chronic kidney disease patients were included. Urinary phospholipids were quantified by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Results: Urinary phosphatidylcholines concentrations (PC 16:0/16:0, 16:0/22:3, 16:0/18:1 and 16:0/18:2) were significantly higher both in glomerulonephritis group (all p < 0.001) and in tubulointerstitial injury group (all p < 0.05) than in healthy control group. Meanwhile, sphingomyelin concentrations (SM 18:1/16:0 and 18:1/18:0) in glomerulonephritis group were significantly higher than those in healthy control group (all p < 0.001). Urinary PCs and SMs were positively correlated with proteinuria but negatively correlated with serum albumin. Meanwhile, PCs were positively correlated with serum creatinine. Conclusion: Our work first demonstrated that urinary phospholipids might be biomarkers for the chronic kidney disease patients. Increased urinary phospholipids in chronic kidney disease patients might result from proteinuria, damaged kidney function or proteinuria induced hypoalbuminemia or lipotoxicity.Keywords
This publication has 15 references indexed in Scilit:
- NGAL and Metabolomics: The Single Biomarker to Reveal the Metabolome Alterations in Kidney InjuryBioMed Research International, 2013
- Urinary L-FABP and its combination with urinary NGAL in early diagnosis of acute kidney injury after cardiac surgery in adult patientsBiomarkers, 2012
- Liquid chromatographic–mass spectrometric analysis of phospholipids. Chromatography, ionization and quantificationBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2011
- Sphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane Study)Metabolomics, 2011
- A comparison of creatinine vs. specific gravity to correct for urinary dilution of cotinineBiomarkers, 2011
- Role of Sphingolipid Mediator Ceramide in Obesity and Renal Injury in Mice Fed a High-Fat DietThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Impaired de Novo Choline Synthesis Explains Why Phosphatidylethanolamine N-Methyltransferase-deficient Mice Are Protected from Diet-induced ObesityJournal of Biological Chemistry, 2010
- Metabolomic identification of potential phospholipid biomarkers for chronic glomerulonephritis by using high performance liquid chromatography–mass spectrometryJournal of Chromatography B, 2007
- High-throughput quantification of phosphatidylcholine and sphingomyelin by electrospray ionization tandem mass spectrometry coupled with isotope correction algorithmBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2004
- 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic dataXenobiotica, 1999